Just in Time: The Most Advanced Supplement for Fighting Flu and Colds

FluShield™ provides major breakthrough in immune-boosting natural medicines

TORONTO, Oct. 26 /CNW/ - Jamieson Laboratories, Canada's largest manufacturer of advanced natural-health products, announced the release of FluShield™, a clinically¹ proven flu-fighting formula that is made with a patented, next-generation echinacea extract known as LPx³.

Echinacea, a traditional herbal medicine that has been long recognized for its immune-stimulating powers, is the most common nutraceutical used in Canada to prevent the flu and common cold. Consumers spend more than $12 million on formulas containing the native North American wildflower in hopes of minimizing the impact of flu, which afflicts 10% to 25% of Canadians each year². Echinacea sales continue to grow at an annual rate of 7%, making it the fastest-growing herbal category in Canada.³

"I've visited the LPx³ fields and manufacturing facility and understand why, after 10 years of development, LPx³ is one of the most effective flu-prevention natural medicines available," says Bryce Wylde, Canada's leading alternative-health expert. "People who use echinacea formulas to boost immunity will instantly recognize the power of LPx³. For anyone who's never tried echinacea, LPx³ will be a revelation in flu prevention."

Exclusively grown and produced in Italy, LPx³ is an advanced form of Echinacea angustifolia chosen from among 40 plant genotypes for its unique potency and effectiveness. Through selective breeding, the plant's medicinal compounds — immune-boosting polysaccharides — have been augmented and concentrated in the roots, resulting in a one-of-a-kind cultivar. Laboratory data on LPx³'s broad spectrum of echinacea compounds prove that it is more effective at turning on the body's important disease-fighting cells, which makes it superior at preventing flu compared to Echinacea purpurea or Echinacea pallida.

"LPx³ is a breakthrough in natural medicine," says Gary Leong, Jamieson's Vice President, Scientific & Technical Affairs. "With LPx³, we've taken a superior natural source and used state-of-the-art science to turn it into the world's most advanced immune-boosting supplement."

LPx³ stands apart because of triple standardization, a pharmaceutical process that captures the most beneficial compounds and removes immune-suppressing isobutylamides, which commonly occur in other echinacea formulas. "Isobutylamides in commercial formulas can inhibit up to 50% of the body's immune-boosting T cells," notes Wylde. "If you don't remove them, echinacea can have a paradoxical effect on the immune response."

In Canada, Jamieson FluShield™ is the only NPN-approved, flu-defence product that contains LPx³ echinacea. Like all Jamieson products, FluShield™ is manufactured according to 360 Pure, which guarantees a minimum of 360 quality-assurance steps that ensure safety, purity, raw-material traceability and consistent active potency. FluShield™ is available at most mass retail stores across Canada for the manufacturer's suggested retail price of $11.99 for 20 capsules or $19.99 for 40 capsules.

About Jamieson Laboratories
Established in 1922, Jamieson Laboratories is Canada's largest manufacturer and distributor of advanced natural-health products and a world-leading innovator in the development of proprietary formulas. All Jamieson products are made at the company's state-of-the-art laboratories in Windsor. With corporate offices in Toronto, Jamieson exports products to more than 50 countries. For more information, visit www.jamiesonvitamins.com or call 1-800-265-5088.

NOTE TO TELEVISION STATIONS: B-Roll available at:
http://cnw.pathfireondemand.com/viewpackage.action?packageid=400

References:
_______________________________

¹ In vitro and in vivo immune stimulating effects of a new standardized Echinacea angustifolia root extract (Polinacea™). P Morazzoni et al. Fitoterapia. Volume 76, Issue 5. July 2005, Pages 401-411.
² ACNielsen Market Track. National Food, Drug, Mass 52 weeks ending August 28, 2010.
³ IBID

For further information: